Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04222972 |
| Title | AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Blueprint Medicines Corporation |
| Indications | |
| Therapies |
Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium |
| Age Groups: | senior | adult |
| Covered Countries | USA |
CKB BOOST